SAN DIEGO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo, which will take place in Philadelphia, Pennsylvania, October 12-16, 2019.
Daré’s Chief Scientific Officer, David Friend, PhD, will present findings from a pharmacokinetic animal study of DARE-FRT1, which is being developed for the prevention of preterm birth and as a new option for luteal phase support following in-vitro fertilization (IVF). DARE-FRT1 is part of Daré’s novel intravaginal ring (IVR) technology platform and is designed to allow for convenient non-invasive, non-oral administration of bio-identical progesterone during a 14-day period.
“The research being highlighted at this year's ASRM meeting reinforces our commitment to develop new treatment options for women at risk for preterm birth and to better support providers and women utilizing progesterone to improve outcomes following an IVF procedure,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
Impaired fecundity (physical difficulties getting pregnant or carrying a pregnancy to live birth) affects an estimated 6.7 million women aged 15-44 in the U.S., or approximately 11% of women of reproductive age, and 25% of infertile couples have more than one factor leading to infertility.1,2 According to Grand View Research, the global IVF market size was valued at $16.68 billion in 2018 and is estimated to expand at a compound annual growth rate of 10.2% during the next seven years. Increases in the cases of infertility and development of advanced technologies were cited as growth drivers.3
“DARE-FRT1 has the potential to continuously deliver bio-identical progesterone in a convenient way during a period of 14 days,” said Dr. Friend. “With approximately 10% of all pregnancies in the U.S. resulting in preterm births,4 and the increasing demand for pregnancy support following IVF procedures, DARE-FRT1 could become an important new option for women and healthcare providers seeking better ways to address these significant unmet needs in women’s health.”
Poster Presentation Information
Poster Number: P-173
Presentation Day: Tuesday, October 15, 2019
Abstract Title: 1761: A Novel Progesterone Releasing Intravaginal Ring for Luteal Phase Support: Pharmacokinetics and Safety in a Sheep Model
Session Topic: IVF Outcome Predictors - Luteal Support
1 – Chandra A, et al., Infertility and Impaired Fecundity in the United States, 1982–2010: Data From the National Survey of Family Growth, National Health Statistics Reports, No. 67, Aug 14, 2013, https://www.cdc.gov/nchs/data/nhsr/nhsr067.pdf
2 – ASRM, https://www.reproductivefacts.org/faqs/quick-facts-about-infertility/
3 – In-Vitro Fertilization (IVF) Market Size, Share & Trends Analysis Report By Type, By Instrument (Disposable Devices, Culture Media, Capital Equipment), By End Use, By Region, And Segment Forecasts, 2019 – 2026, Mar 2019, https://www.grandviewresearch.com/industry-analysis/in-vitro-fertilization-market
4 – Martin J, et al., Births: Final Data for 2017, National Vital Statistics Reports, Vol. 67, No. 8, Nov 7, 2018, https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_08-508.pdf1
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of the company's website mentioned above.
Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Daré’s commitment to developing new treatment options for preventing preterm birth and improving outcomes following IVF procedures, DARE-FRT1’s potential to deliver bio-identical progesterone continuously over 14 days in a convenient, non-systemic and non-invasive way, and DARE-FRT1’s potential to prevent preterm birth and support pregnancy maintenance following IVF procedures. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risk and uncertainties related to: Daré’s ability to raise additional capital when and as needed, to advance its product candidates; Daré’s ability to develop, obtain regulatory approval for, and commercialize its product candidates; the failure or delay in starting, conducting and completing clinical trials or obtaining FDA or foreign regulatory approval for Daré’s product candidates in a timely manner; Daré’s ability to conduct and design successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; the risk that promising results in pre-clinical studies may not be replicated when a product candidate is tested in human subjects; Daré’s ability to retain its licensed rights to develop and commercialize a product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product candidates; developments by Daré’s competitors that make its product candidates less competitive or obsolete; Daré’s dependence on third parties to conduct clinical trials and manufacture clinical trial material; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré’s product candidates which could expose its products to competition from other formulations using the same active ingredients; the risk of failure associated with product candidates in preclinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund; and disputes or other developments concerning Daré’s intellectual property rights. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors on behalf of Daré Bioscience, Inc.:
Media on behalf of Daré Bioscience, Inc.:
Source: Daré Bioscience